Dostarlimab vs Penpulimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Dostarlimab
Marketed by GlaxoSmithKline and partners
NCT04655976 · Phase 2/3 · active, not recruiting
Patients were randomly assigned to three arms (758 enrolled) with docetaxel as the active comparator, but the study was open label, with no masking. The primary endpoint, overall survival, was not significantly improved by dostarlimab plus docetaxel (HR 0.96, 95% CI 0.77 to 1.20, p=0.37) or by the triplet with cobolimab (HR 0.85, 95% CI 0.68 to 1.06, p=0.08), so the primary comparisons were not met.
Next expected readout: January 2027 · NCT06879717 (registry estimate)
Reported efficacy
Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks); Overall Survival (OS) (Arm B Versus Arm C) (Up to approximately 234 weeks): Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) (missed)
Result source: NCT04655976
Penpulimab
Marketed by Akeso and partners
NCT03866993 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.
Reported efficacy
Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)
Result source: NCT03866993
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dostarlimab | Penpulimab |
|---|---|---|
| PFS, median | 4.4 vs 4.1vs DocetaxelNCT046559762 other results
| 8.6 vs 4.2a+4.4 vs placeboNCT03866993 |
| OS, median | 11.9 vs 11.3vs DocetaxelNCT046559763 other results
| —Not posted · NCT03866993 |
| ORR | 18.7% vs 14.5%vs DocetaxelNCT046559762 other results
| —Not posted · NCT03866993 |
| Duration of response, median | 8.3 vs 8.8vs DocetaxelNCT046559762 other results
| —Not posted · NCT03866993 |
PFS, median
- Dostarlimab
- 4.4 vs 4.1vs DocetaxelNCT04655976
2 other results
- 4.2 vs 4.1 NCT04655976
- 4.4 NCT03308942
- Penpulimab
- 8.6 vs 4.2a+4.4 vs placeboNCT03866993
OS, median
- Dostarlimab
- 11.9 vs 11.3vs DocetaxelNCT04655976
3 other results
- 11.8 vs 11.3 NCT04655976
- 11.9 NCT04655976
- 11.8 NCT04655976
- Penpulimab
- —Not posted · NCT03866993
ORR
- Dostarlimab
- 18.7% vs 14.5%vs DocetaxelNCT04655976
2 other results
- 18.3% vs 14.5% NCT04655976
- 9.1% NCT03308942
- Penpulimab
- —Not posted · NCT03866993
Duration of response, median
- Dostarlimab
- 8.3 vs 8.8vs DocetaxelNCT04655976
2 other results
- 7.1 vs 8.8 NCT04655976
- 21.5 NCT03308942
- Penpulimab
- —Not posted · NCT03866993
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dostarlimab: 3 of 4 rows · Penpulimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dostarlimab | Penpulimab |
|---|---|---|
| Dropout rate | 25.6%Cobolimab + Dostarlimab + Docetaxea NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results21.6%Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 —Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | — |
| Discontinued due to AEs | —Cobolimab + Dostarlimab + Docetaxea NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results—Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 —Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | — |
| Serious AEs | 33.8%Cobolimab + Dostarlimab + Docetaxea NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results42.7%Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 58.3%Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | — |
| Most frequent reported AEs | a anaemia 34.8% neutropenia 31.5% fatigue 29.5% NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 2 more resultsanaemia 31.5% fatigue 29.8% diarrhoea 29.5% NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 nausea 58.3% diarrhoea 50% fatigue 41.7% NCT03308942 · Phase 2 · registry result, not featured evidence · combination | — |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dostarlimab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Penpulimab's landscape